AC Immune (ACIU) Income from Continuing Operations (2015 - 2026)
AC Immune (ACIU) posted quarterly Income from Continuing Operations of 18900946.3 for Q1 2026, up 10.7% year-over-year from 17074453.71 in Q1 2025, and down 5.1% quarter-over-quarter from 17983063.42 in Q4 2025.
Powered by 
Analysis
AC Immune (ACIU) Income from Continuing Operations (2015 - 2026) Analysis & Trends
AC Immune (ACIU) has reported Income from Continuing Operations for 12 consecutive years, with 18900946.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 10.7% year-over-year to 18900946.3; the TTM figure through Mar 2026 stood at 82302232.45 (down 41.87% YoY), while the FY2025 annual figure was 84968134.06, down 46.21% from the prior year.
- Income from Continuing Operations retreated to 18900946.3 in Q1 2026 per ACIU's latest filing, from 17983063.42 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6351602.46 in Q3 2024 and bottomed at 25593986.06 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 17360965.7 across 5 years, with a median of 18927913.25 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 137.06% — and 2025, when it tumbled 412.11%.
- AC Immune's Income from Continuing Operations stood at 19457720.74 in 2022, then jumped by 72.53% to 5345914.91 in 2023, then slumped by 237.25% to 18029196.07 in 2024, then increased by 0.26% to 17983063.42 in 2025, then declined by 5.1% to 18900946.3 in 2026.
- Business Quant data shows ACIU's Income from Continuing Operations at 18900946.3 in Q1 2026, 17983063.42 in Q4 2025, and 19824236.68 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - | 2.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.37 Mn |
| Mar 31, 2026 | -18.90 Mn |
| Dec 31, 2025 | -17.98 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -21.17 Mn |
| Dec 31, 2024 | -18.03 Mn |
| Sep 30, 2024 | 6.35 Mn |
| Jun 30, 2024 | -25.17 Mn |
| Mar 31, 2024 | -20.46 Mn |
| Dec 31, 2023 | -5.35 Mn |
| Sep 30, 2023 | -17.14 Mn |
| Jun 30, 2023 | -18.71 Mn |
| Mar 31, 2023 | -18.93 Mn |
| Dec 31, 2022 | -19.46 Mn |
| Sep 30, 2022 | -13.99 Mn |
| Jun 30, 2022 | -20.39 Mn |
| Mar 31, 2022 | -20.40 Mn |
| Dec 31, 2021 | -23.07 Mn |
| Sep 30, 2021 | -17.34 Mn |